“Before Boldr Futures stepped in, our radiopharmaceutical delivery business was bleeding resources and lacked a strategic vision. Within three years, they helped us close unprofitable divisions, modernize our TMS, and rebuild our brand—leading to a 5X jump in valuation and a lucrative exit. Now, we’re thriving under a new ownership model that respects our legacy.